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Abstract
Introduction: The effectiveness of treatment of painful diabetic polyneuropathy remains unsatisfactory. The aim of this study was to 
compare effects of intravenous vs. subcutaneous insulin delivery in patients with diabetic symmetric sensorimotor polyneuropathy on 
pain relief, the quality of life, sleep disturbance, and the nerve conduction.
Material and methods: Thirty-four patients with diabetic polyneuropathy (mean age 62 ± 10 years, duration 17 ± 10 years), who reached 
a pain score over 40 mm on the VAS scale, HbA1c 7.5–10%, were randomly assigned to continuous intravenous insulin infusion (examined 
group) and multiple injections (control subjects). Before and after five days of the insulin treatment the effects on pain relief (SFMPQ-VAS), 
the quality of life improvement (EuroQol EQ-5D), and sleep disturbances (AIS) were assessed.
Results: Both groups experienced significant pain reduction, improvement of the quality of life, and reduction of sleep disturbances, i.e. 
a VAS in the study group of 69 ± 14 mm before treatment vs. 40 ± 19 mm after treatment (p < 0.001), and in control subjects 66 ± 16 mm 
vs. 47 ± 17 mm (p < 0.001).
No difference in level of pain intensity reduction between the groups studied was found.
Conclusions: Intensification of insulin treatment applied for five days results in improvement of the physical condition of patients with 
painful diabetic polyneuropathy, through pain relief, and improvement of the quality of life and sleep quality. The efficacy of insulin 
intravenous infusion and multiple injections is comparable.  (Endokrynol Pol 2015; 66 (3): 237–243)
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Streszczenie
Wstęp: Skuteczność leczenia bólowej polineuropatii cukrzycowej jest niesatysfakcjonująca. Celem badania była ocena wpływu dożylnej 
lub podskórnej podaży insuliny u chorych z symetryczną bólową polineuropatią czuciowo-ruchową na: stopień nasilenia bólu, poprawę 
jakości życia, ilościową i jakościową ocenę snu oraz przewodnictwo czuciowo-ruchowe w nerwach strzałkowym i łydkowym.
Materiał i metody: 34 chorych z cukrzycową polineuropatią (średni wiek chorych 62 ± 10 lat, czas trwania cukrzycy 17 ± 10 lat), z nasi-
leniem bólu > 40 mm w skali VAS i HbA1c 7,5–10% zostało losowo przydzielonych do grupy otrzymującej dożylny wlew insuliny (grupa 
badana) lub podskórne wstrzyknięcia insuliny w modelu wielokrotnych wstrzyknięć (grupa kontrolna). Oceniono wpływ leczenia na 
nasilenie bólu (SFMPQ-VAS), jakość życia (EuroQol EQ-5D) i zaburzenia snu (AIS). 
Wyniki: Zaobserwowano znamienne zmniejszenie nasilenia bólu, poprawę jakości życia oraz snu. VAS w grupie badanej 69 ± 14 mm 
przed i 40 ± 19 mm po leczeniu (p < 0,001), w grupie kontrolnej odpowiednio 66 ± 16 mm i 47 ± 17 mm (p < 0,001). Nie obserwowano 
różnic pomiędzy grupami. 
Wnioski: Intensyfikacja insulinoterapii stosowana przez 5 dni powoduje poprawę stanu klinicznego chorych na cukrzycę powikłaną 
bólową polineuropatią poprzez: zmniejszenie nasilenia bólu, poprawę jakości życia, poprawę parametrów snu. Zastosowanie wlewu 
dożylnego insuliną ma porównywalną skuteczność jak iniekcje podskórne.  (Endokrynol Pol 2015; 66 (3): 237–243)
Słowa kluczowe: cukrzyca; powikłania cukrzycy; bólowa polineuropatia cukrzycowa; insulinoterapia; dożylna podaż insuliny
Introdution
Diabetic neuropathy is a heterogeneous group of 
symptoms and/or signs of dysfunction of the periph-
eral nervous system resulting from diabetes mellitus, 
provided that other possible causes are ruled out [1]. 
Symmetric chronic sensorimotor polyneuropathy that 
usually develops slowly and insidiously is the most 
common clinical form of diabetic neuropathy. It is 
a serious problem in modern diabetology. Pain is the 
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of intravenous vs. subcutaneous insulin administration 
in patients with diabetes mellitus accompanied by 
symmetric painful sensorimotor polyneuropathy on 
the following parameters: pain relief, improvement of 
quality of life, and quantitative and qualitative sleep 
assessment. These aims were assessed based on a ran-
domised, patient-blinded study.
Material and methods
The study enrolled 34 patients (16 men and 18 women) 
with uncontrolled diabetes mellitus with sensorimotor 
polyneuropathy after ruling out other causes of poly-
neuropathy, who at the study start scored at least 40 mm 
on a 100-mm visual analogue scale (VAS), a part of the 
Short-Form McGill Pain Questionnaire (SFMPQ) [8]. 
Exclusion criteria included other than diabetic causes 
of polyneuropathy and HbA1c < 7.5% and > 10%. The 
study was conducted in in-patient conditions. Patients 
were fully informed of the aim and conduct of the study. 
All study subjects provided written consent. The study 
was approved by the Ethics Committee of the Silesian 
Medical University in Katowice. Table 1 presents the 
clinical characteristics of the study subjects.
All study subjects completed the following question-
naires twice (before and on day 5 of the study):
 — Short-Form McGill Pain Questionnaire (SFMPQ);
 — quality of life questionnaire EuroQol EQ-5D VAS 
Worksheet;
 — sleep disturbance questionnaire AIS (Athens In-
somnia Scale).
At the time of hospital admission all study subjects 
were questioned about the duration of their diabetes 
mellitus and its type, previous antidiabetic therapy and 
treatment of painful polyneuropathy, co-morbidities, 
and the presence of other late diabetic complications. 
Anthropometric parameters were collected and venous 
blood samples were withdrawn for laboratory tests: 
HbA1c, lipid profile. A five-item neurological examina-
tion of the feet was performed involving assessment 
of perception of touch, vibrations, pain, temperature, 
and deep reflexes to confirm diabetic polyneuropathy. 
Furthermore, sensorimotor conduction was assessed by 
measuring conduction velocity, amplitude, and latency 
of F wave in peripheral motor and sensory nerves in 
the lower extremities: peroneal nerve (a motor nerve) 
and sural nerve (a sensory nerve). During the study 
the patients continued their previous therapy. No other 
drugs were added that might have affected neuropathic 
pain. Patients received intravenous insulin infusion (the 
study group) or multiple subcutaneous insulin injec-
tions (the control group) for five days. Patients were 
randomised into study groups using block-four ran-
domisation. Blood glucose concentration was measured 
basic clinical problem in patients with advanced diabetic 
polyneuropathy. Patients usually report symmetric pain 
in the lower extremities, occurring spontaneously, with-
out any discernible cause. Studies have demonstrated 
that patients with such pain experience significantly 
reduced quality of life. Therefore, if the treatment ef-
fectiveness is assessed, one should consider subjective 
patient’s experiences related to intensity of pain and 
improvement of quality of life. The drugs used in the 
treatment of diabetic neuropathy include agents that 
act on the causes of the neuropathy and symptomatic 
agents. Drugs that are directed at the pathogenesis of 
diabetic polyneuropathy and recommended by the 
Polish Society of Diabetology in line with international 
guidelines include α-lipoic acid, benfotiamine, and 
angiotensin converting enzyme inhibitors (ACE-I) [2]. 
Among the symptomatic drugs, tricyclic antidepres-
sants (amitriptyline) and anticonvulsants including 
carbamazepine, gabapentin, and pregabaline exhibit 
the highest effectiveness [3, 4]. Many patients use 
analgesics, most commonly paracetamol and other 
non-steroidal anti-inflammatory drugs (NSAIDs) that 
exhibit good analgesic properties.
Due to the complex and multifactorial pathogenesis 
of diabetic neuropathy in which hyperglycaemia is an 
aetiological factor, the best metabolic control of diabetes 
is the basic causative effect. Insulin formulations are the 
principal group of drugs used in the treatment of pa-
tients with poorly controlled diabetes mellitus. Insulin 
directly and indirectly affects intracellular metabolism 
in the majority of cells in the body. Physiological ef-
fects of insulin differ with regard to the time of their 
appearance. These effects can be classified as follows: 
rapid, e.g. glucose, amino acid transport; intermediate 
— that appear after a few minutes, e.g. the effect on 
the activity of enzymatic proteins; and delayed, which 
manifest after a few hours or days, e.g. stimulation of 
cellular proliferation and growth [5].
Based on multiple randomised, multicentre clinical 
trials, e.g. DCCT (Diabetes Control and Complication 
Trial), that assessed patients with type 1 diabetes mel-
litus, and the UKPDS (United Kingdom Prospective 
Diabetes Study), which enrolled patients with type 2 
diabetes mellitus, it is known that metabolic control 
is a crucial element of treatment of painful diabetic 
polyneuropathy [6, 7]. In this picture insulin is a tool 
for the achievement of normal blood glucose concentra-
tion. Concurrently, due to the effect of insulin on the 
above-mentioned processes, it can be a drug affecting 
neuropathic pain. It is unknown whether intravenous 
insulin delivery in patients with poorly controlled dia-
betes mellitus is superior to subcutaneous delivery in 
patients with symmetric painful sensorimotor polyneu-
ropathy. The aim of this study was to assess the effects 
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at least eight times per day. Target glucose concentration 
values were: fasting 70–110 mg/dL (3.9–6.1 mmol/L), 
and 2 hours after a meal < 140 mg/dL (7.77 mmol/L). 
The study group receiving intravenous insulin received 
an infusion of 50 mL 0.9% NaCl + 50 units of aspart 
insulin using an infusion pump Ascor 22 with adjust-
able flow depending on blood glucose concentration. 
The insulin dose was adjusted based on serum glucose 
concentration, according to the protocol that was pre-
pared based on the Yale protocol [9]. Patients treated 
with subcutaneous insulin received insulin aspart sc 
before each meal at a dose titrated to blood glucose 
concentration and a slow intravenous infusion of 0.9% 
NaCl (as a placebo). If blood glucose concentration two 
hours after a meal was higher than the target value 
(< 140 mg/dL (7.77 mmol/L)), additional subcutaneous 
insulin was administered to correct hyperglycaemia. 
After five days of intensive treatment the following 
were repeated: five-item neurological examination of 
the feet and examination of sensorimotor conduction.
Results were presented as means ± SD, and if their 
distribution was not normal — as medians and inter-
quartile ranges. The following were used to assess the 
differences: t-Student test, and if the distribution was 
not normal: Mann-Whitney U test or Wilcoxon signed-
rank test.
Results
Table I presents characteristics of the study groups. 
Patients qualified to intravenous therapy (the study 
group) had significantly higher average blood glucose 
concentration at the start of the study when compared 
to patients treated with subcutaneous insulin (the 
control group). The other parameters did not differ 
between the groups.
Figure 1 presents individual values in pain inten-
sity before and after five days of therapy. The baseline 
values of VAS were 69 ± 14 mm in the examined group 
and 66 ± 16 mm in control subjects, respectively (ns). 
After five days of treatment a significant (p < 0.001) 
similar reduction of pain intensity was observed in 
both groups, respectively 40 ± 19 mm vs. 40 ± 17 mm. 
No difference in the level of decrease was observed 
between the groups studied (ns). Pain intensity did 
not differ between the groups. Table II presents evalu-
ation of quality of life on day one and day five of the 
therapy, based on the EuroQol EQ-5D VAS Worksheet. 
At baseline the examined group reported statistically 
significantly better quality of life compared to control 
subjects (p < 0.05). After five days of therapy a signifi-
cant improvement of quality of life was observed only 
in control subjects (p < 0.001). A statistically significant 
improvement of sleep disturbances was observed on 
day five both in the examined group and in control 
subjects (p < 0.01; p < 0.05, respectively) (Table III).
Sensorimotor conduction was evaluated in 30 study 
subjects (16 from the study group and 14 from the 
control group). Evidence of polyneuropathy in this 
investigation was not found in 3 of 4 patients excluded 
from the evaluation of conduction, while one patient 
was an outlier. Table IV presents values of sensorimotor 
conduction. Before treatment initiation both groups 
demonstrated reduced amplitude of evoked potentials 
Figure 1. Individual values of pain intensity (VAS score) in 
patients treated with intravenous insulin (examined group) and 
subcutaneously (control subjects)
Rycina 1. Indywidualne wartości nasilenia bólu (wg skali VAS) 
u chorych leczonych dożylnie insuliną (grupa badana) i insuliną 
podskórnie (grupa kontrolna)
Table I. General characteristics of the study group classified 
into subgroups treated with intravenous or subcutaneous 
insulin. Data are presented as means ± SD
Tabela I. Ogólna charakterystyka badanych grup leczonych 
insuliną dożylnie i podskórnie (Dane podano jako średnie ± SD)
All patients 
n = 34
Examined 
group  
n = 17
Control 
subjects  
n = 17
Age (years) 62 ± 10 60 ± 9 63 ± 10
Sex (M/F) 16/18 10/7 6/11
Disease duration (years) 17 ± 10 19 ± 12 15 ± 8
Duration of insulin therapy (years) 12 ± 12 11 ± 14 12 ± 9
BMI [kg/m²] 32.5 ± 4 32.8 ± 4 32.2 ± 5
HbA1c 8.7 ± 1.3 8.8 ± 1.2 8.5 ± 1.3
Mean blood glucose 
concentration on day 1 [mg/dL]
176 ± 36 189 ± 42 163 ± 24†
Mean glucose concentration on 
day 5 [mg/dL]
135 ± 26 143 ± 27 128 ± 24
†p < 0.05 vs. the study group
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from investigated nerves and prolonged end latency. 
Reduced conduction velocity in the sural nerve was 
found both in the examined group and in control 
subjects, while in the peroneal nerve – only in control 
subjects. No significant differences were found between 
the groups with regard to any of the parameters of sen-
sorimotor conduction. Improved conduction velocity 
in the sural nerve versus the pretreatment values was 
found after five days of intravenous insulin therapy 
(p < 0.05). Improved conduction velocity after therapy 
was not found in control subjects in the sural nerve or 
in the peroneal nerve.
Discussion
This randomised, patient-blinded study demonstrated 
that intensification of insulin therapy results in im-
proved general condition in patients with painful 
diabetic polyneuropathy, through reduction of neu-
ropathic pain and improvement of sleep parameters. 
Intravenous insulin delivery exhibits comparable ef-
ficacy to subcutaneous injections.
Available literature data indicates that it is the first 
study to compare the effects of intravenous and subcu-
taneous insulin delivery on the intensity of neuropathic 
pain in diabetic subjects.
Before inclusion in the study the patients were 
treated with both oral antidiabetic drugs (6 patients), 
oral drugs in combination with insulin (11 patients), 
and insulin monotherapy (17 patients). No differences 
were found between these groups with regard to the 
analysed parameters of glycaemic control. Previous 
treatment could have affected the results obtained; 
however, the aim of the study was to evaluate whether 
intravenous insulin delivery is superior to subcutane-
Table II. Evaluation of quality of life — EuroQol EQ-5D VAS 
Worksheet (0–100 points) at baseline (EQ 0) and day five of 
the study (EQ 1). Data are presented as means ± SD
Tabela II. Ocena jakości życia — skala EuroQol EQ-5D VAS 
(0–100 punktów) wyjściowo (EQ 0) i po 5 dniach badania 
(EQ 1). Dane podano jako średnie ± SD
Examined group 
n = 17
Control subjects 
n = 17
EQ0 — at baseline  57 ± 14† 42 ± 19
EQ1 — day five of the 
study
63 ± 18  61 ± 15***
D EQ 7† 19
†p < 0.05 vs. the control group 
***p < 0.001 vs. baseline
Table III. Quantitative sleep evaluation according to Athens 
Insomnia Scale at baseline (AIS 0) and day five of the study 
(AIS 1). Data are presented as means ± SD
Tabela III. Ocena jakości snu wg Ateńskiej Skali Bezsenności 
wyjściowo (ASIS 0) i po 5 dniach badania (ASIS 1). Dane 
przedstawiono jako średnie ± SD
Examined 
group (E) 
n = 17
Control 
subjects (C) 
n = 17
Number of 
subjects 
with AIS 
> 10 
n (%) 
Group E
Number of 
subjects 
with AIS 
> 10 
n (%) 
Group C
E vs. C
AIS 
0 — at 
baseline
13 ± 5 12 ± 5 13
(76%)
12
(71%)
ns
AIS 1 — 
day five of 
the study
 9 ± 5** 9 ± 5* 6*
(35%)
5*
(29%)
ns
*p < 0.05 vs. baseline 
**p < 0.01 vs. baseline
Table IV. Parameters of sensorimotor conduction in peripheral nerves at baseline and after five days of therapy. Data are 
presented as medians and interquartile ranges
Tabela IV. Parametry przewodnictwa czuciowo-ruchowego w nerwach obwodowych wyjściowo i po 5 dniach leczenia. Dane 
przedstawiono jako mediany i przedziały ufności
Before treatment After 5 days of therapy Before treatment After 5 days of therapy E vs. C
Examined group (E) n = 16 Control subjects (C) n = 14
Sural (sensory) 
nerve
Conduction velocity 
SCV [m/s]
32.5 (26.5–42) 38 (29–45) * 33 (25–38) 36 (31–40) ns
Amplitude [µV] 3.4 (1.05–7.45) 2.6 (1.5–6.2) 2.4 (1.3–6.2) 3.3 (1.1–4) ns
Latency [ms] 3.85 (3–5.2) 3.4 (3.2–4) 4.4 (3.4–5.9) 3.7 (3.3–4.4) ns
Peroneal 
(motor) nerve
Conduction velocity 
MCV [m/s]
43 (40–46) 43 (39–47) 41 (36–49) 40 (38–47) ns
Amplitude [mV] 2.85 (2.35–4.1) 2.8 (1.4–5) 2 (0.8–3.7) 1.9 (0.8–4.8) ns
Latency [m/s] 13.8 (11.9–14.65) 13.3 (12.3–15.3) 13 (11.7–15.2) 13.7 (12.4–16.9) ns
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ous injections with regard to the effect on the analysed 
parameters. Therefore, we can assume that the treat-
ment prior to inclusion in the study had no effect on 
the obtained results, which supported the fact that no 
intergroup differences were observed irrespective of 
the method of insulin administration.
The group receiving intravenous insulin and the 
group treated with subcutaneous insulin were homo-
geneous with regard to anthropometric measurements 
as well as the results of laboratory tests (HbA1c). Mean 
blood glucose concentration differed between the study 
groups despite patient randomisation. Higher values 
of 24-hour mean glucose concentration were found 
in the examined group, but blood glucose reduction 
after five days of treatment was similar in both groups 
(mean reduction of blood glucose concentration was 
approximately 40 mg/dL — 2.22 mmol/L).
The patients were qualified to treatment based on 
clinical data and five-item neurological examination. 
According to literature data, the presence of at least two 
pathologies in this examination indicates peripheral 
polyneuropathy with sensitivity exceeding 87% [10]. 
All study subjects met this criterion. Some authors 
believe that simple diagnostic tests are sufficient to 
diagnose diabetic neuropathy [11], while others sug-
gest expansion of the diagnostic work-up and addition 
of electroneurophysiological investigations to evalu-
ate amplitude, latency, and velocity of conduction in 
sensory and motor nerves. To confirm the presence 
of sensorimotor polyneuropathy and to evaluate the 
efficacy of provided treatment, all subjects underwent 
investigation of sensorimotor conduction both before 
and after five days of insulin therapy. At baseline 31 of 34 
study subjects qualified to the investigation, exhibited 
pathological sensorimotor conduction, and a neurolo-
gist diagnosed them with diabetic polyneuropathy. No 
other pathologies were found in the electroneurophysi-
ological examination in the remaining three patients. 
Therefore sensitivity of the five-item neurological exa-
mination in this study (91%) was close to that reported 
in the literature.
Before the commencement of the study, potential 
study subjects underwent very careful selection, and 
particular emphasis was put on the nature of pain of the 
lower extremities and time of the day at which the pain 
was most severe. Besides clinical symptoms, scoring 
by patients at least 40 mm on the VAS scale, which was 
a part of the SFMPQ questionnaire, was a key inclusion 
criterion [8]. No superiority of either method of treat-
ment was found with regard to evaluation on the VAS 
scale. Lack of differences between patients may have 
resulted from a very significant factor of therapeutic 
efficacy, i.e. the placebo effect. Commonly observed 
analgesic efficacy of agents that do not exhibit such 
properties results, for example, from patient expecta-
tions of analgesic effects that are converted into a typical 
conditional reflex (“a drip infusion always results in 
pain resolution”). Pain-related behaviour is an effect of 
patient views and reactions on pain and furthermore 
can be modified by the environment [12]. A similar 
effect of reduction of pain intensity irrespective of the 
provided treatment was observed in most of the stud-
ies that evaluated various forms of therapy [3, 4, 13].
The analysis of the effects of the provided treat-
ment should not overlook a subjective evaluation of 
quality of life by patients themselves. A quality of life 
questionnaire EuroQol EQ-5D VAS Worksheet was 
used in this study. Intergroup differences in quality of 
life were found even before the treatment initiation. 
Patients from the study group had better quality of life 
than patients from the control group and this difference 
was statistically significant. Since both groups were 
homogeneous with regard to age, sex, disease duration, 
and level of metabolic control, these parameters did not 
affect the evaluation of the quality of life. Furthermore, 
this evaluation could not have been affected by the use 
of antidepressants because tricyclic antidepressants 
were used only by one person from the study group 
and three subjects from the control group, and the treat-
ment remained unchanged during the study. Analysis 
of other variables indicated that 70% of patients from 
the control group and only 41% patients from the study 
group had a history of attempts of treatment of painful 
sensorimotor polyneuropathy. However, these attempts 
were inadequately effective to improve the quality 
of life. On the basis of observations of patients with 
chronic pain it is known that treatment failures mark-
edly impair mood and generate negative emotions in 
patients such as anger, anxiety, and aggression, which 
result in impaired quality of life [14]. It is possible that 
a factor of failed therapy that was more prevalent in 
the control group contributed to initially worse qual-
ity of life in this group. Evaluation of the quality of life 
after five days of therapy demonstrated a significant 
improvement in patients receiving subcutaneous insu-
lin, while patients from the study group also exhibited 
improvement in this regard; however, probably due 
to better quality of life at baseline this change did not 
reach statistical significance.
The Athens Insomnia Scale was used to evaluate 
sleep disturbances [15]. Before the study onset 76% 
of patients from the study group and 71% of patients 
from the control group reported significant sleep dis-
turbances, scoring more than 10 points on the AIS scale. 
Numerous studies emphasise the widespread problem 
of sleep disturbances, in particular in patients with 
chronic somatic disorders [16]. Patients with painful 
sensorimotor polyneuropathy very often complain of 
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sleep disturbances, which have been confirmed in the 
presented study. Evaluation of sleep changes demon-
strated a significant improvement in the quantitative 
evaluation of sleep that correlated with reduction of 
pain complaints and improvement of quality of life. The 
obtained results were similar for both patients in the 
intravenous and subcutaneous insulin groups. After five 
days of therapy significant sleep disturbances were ob-
served only in six patients in the study group (35%) and 
in five patients from the control group (29%). Despite the 
fact that patients were woken up at least twice during 
each night to measure their blood glucose concentration, 
they considered their night’s rest as satisfactory. One can 
conclude that improvement of sleep was significantly 
associated with reduction of neuropathic pain.
Available literature data indicates that insulin affects 
peripheral nerves not only indirectly, through reduction 
of hyperglycaemia, but also directly. Studies in rats with 
diabetes induced by streptozotocin have documented 
the presence of insulin receptors in neuronal cell bodies 
and in axons. Small insulin concentration delivered suba-
rachnoidally did not result in hyperglycaemia reduction, 
but it improved velocity of conduction in the peripheral 
nerves [17]. Most probably direct stimulation of insulin 
receptors and IGF receptors results in beneficial effects on 
neurofilament synthesis (involved in impulse conduction 
in the axon), protects the neuron from apoptosis induced 
by hyperglycaemia, and improves optimal mitochondrial 
function. Mitochondria are the source of most adenosine 
triphosphate (ATP), which is the source of energy for 
highly metabolically active neurons [17, 18].
The process of impulse conduction in nervous fibres 
requires normal generation of resting potential, which 
in turn is a prerequisite for electrical changes termed 
action potentials. The membrane potential is affected 
by passive diffusion of K+, Na+, Cl-, and other ions 
through the plasmatic membrane and their active trans-
port using sodium-potassium pump based on a special 
transporting enzyme — adenosine triphosphatase 
activated by ions Na+ and K+ (Na+K+ATP-ase) [5]. 
Reduced activity of the sodium-potassium pump 
was found in diabetic patients [19]. Hyperglycaemia 
is one of the factors that negatively affect the above-
mentioned physiological processes. Insulin not only 
reduces hyperglycaemia, but it possibly also indirectly 
affects, through activation of receptors in the neurons 
and axons, physiological generation of resting, action 
potential, and conduction in the neurons. Effect of 
insulin on ionic transport is rapid and provides im-
mediate effect. Furthermore, continuous intravenous 
insulin infusion guarantees its activity throughout the 
24 hours, removes factors resulting in insulin resistance, 
and facilitates dosage adjustment depending on current 
serum glucose concentration.
Parameters of sensorimotor conduction in the 
nerves: peroneal (a motor nerve) and sural (a sensory 
nerve) were analysed to more objectively evaluate the 
effects of intravenous insulin on diabetic polyneu-
ropathy. A significant improvement of conduction 
velocity in the sural nerve was observed after intra-
venous insulin therapy. Literature data indicates that 
long-term glycaemic control reduces progression of 
impairment of conduction velocity both in sensory 
nerves and in the motor ones. The eight-year Oslo 
Study conducted by Amthor et al. demonstrated 
beneficial effects of normal glucose concentration on 
peripheral nerve function, since improvement of both 
conduction velocity and amplitude in sensory nerves 
was found. Parameters of sensorimotor conduction 
were improved in all study groups in patients with 
type 1 diabetes mellitus, but the greatest benefits were 
found in patients receiving continuous subcutaneous 
insulin infusion (versus conventional therapy and 
multiple subcutaneous injections) [20]. Consequently, 
the mode of insulin delivery affects the conduction 
velocity in the peripheral nerves. Observed improve-
ment of conduction velocity in the sural (sensory) 
nerve after five days of treatment in patients receiving 
intravenous insulin correlated with results of clinical 
and experimental studies.
In summary, even short-term intensification of 
hypoglycaemic therapy reduces complaints related to 
diabetic polyneuropathy. The mode of insulin delivery is 
of secondary importance. Improvement of the patient’s 
clinical condition depends on normalisation of blood glu-
cose concentration and, as it seems, on the placebo effect.
Conclusions
Intensification of insulin therapy used for five days 
results in improvement of the clinical condition of 
patients with diabetes mellitus complicated by painful 
polyneuropathy, through:
 — pain relief,
 — improvement of quality of life,
 — improvement of sleep parameters.
Intravenous insulin infusion has comparable ef-
ficacy to subcutaneous injections. 
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